What Is Ipamorelin?

Ipamorelin is a synthetic peptide made of only five amino acids, designed at Novo Nordisk in the 1990s to make the pituitary gland release growth hormone without raising other hormones alongside it. It works by binding the ghrelin receptor, has never been approved as a drug anywhere, and the only company that tested it in a disease population shelved the program after its trial failed to beat placebo.

A five-amino-acid peptide, deliberately irregular

Ipamorelin's sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2 — a pentapeptide, far shorter than the 15-to-45-amino-acid chains typical of most peptide drugs. Three of its five residues aren't standard amino acids at all: Aib (alpha-aminoisobutyric acid), D-2-Nal (D-2-naphthylalanine), and D-Phe (D-phenylalanine), the "D" denoting a mirror-image form the body's own ribosomes don't build proteins from. FDA's 2024 evaluation of the compound described it plainly as "a five amino acids peptide containing unnatural amino acids," and noted that comparatively little is known about how peptides built this way behave structurally, which complicates characterizing the finished material chemically.

Chemists at Novo Nordisk reached this sequence by working backward from a longer peptide, GHRP-1 (growth hormone-releasing peptide 1). Raun and colleagues, who first described the result in a 1998 paper in the European Journal of Endocrinology, reported that ipamorelin came from truncating the central alanine-tryptophan dipeptide at the core of GHRP-1's structure, then testing which shortened variants kept GHRP-1's hormone-releasing activity.

How it's supposed to work

Ipamorelin binds the ghrelin receptor — formally the growth hormone secretagogue receptor, GHSR-1a — the same receptor the stomach-derived hunger hormone ghrelin activates. In rats and pigs, Raun's 1998 paper reported that ipamorelin released growth hormone with potency and effectiveness comparable to GHRP-6, an earlier secretagogue in the same family, through what the pharmacological profile indicated was a GHRP-type receptor rather than the separate GHRH receptor pathway.

The selling point, then and now, is selectivity. Older ghrelin-receptor agonists such as GHRP-6 and GHRP-2 also raise adrenocorticotropic hormone (ACTH) and cortisol as a side effect of activating that same receptor. Raun's group reported that ipamorelin did not meaningfully raise either one in their animal models, even at doses more than 200 times what was needed to trigger growth-hormone release — a result the authors described as making ipamorelin the first growth-hormone secretagogue-receptor agonist with a selectivity profile resembling GHRH's own.

What has actually been tested, and on whom

The published evidence splits into three distinct stages, each in a different kind of subject, and the distinction matters.

The 1998 Raun paper is animal pharmacology — rats and pigs, not people. The next step moved into humans but stayed at the basic-pharmacology stage: in 1999, Gobburu and colleagues gave ipamorelin by short intravenous infusion to 40 healthy male volunteers, eight men at each of five ascending dose levels, and modeled how the compound moved through the body and how growth hormone responded. They reported a short elimination half-life of about two hours, blood levels that rose in proportion to dose, and a single, time-limited burst of growth-hormone release after each infusion, with far more person-to-person variation in the hormone response than in the drug's own pharmacokinetics.

The only disease population ipamorelin has been tested in is reported in a 2014 trial by Beck and colleagues, published as the "Ipamorelin 201 Study Group" — a multicenter, randomized, placebo-controlled phase II study in 117 adults recovering from open or laparoscopic bowel-resection surgery, built around postoperative ileus, the temporary shutdown of gut motility that commonly follows abdominal surgery. Patients received intravenous ipamorelin or a placebo twice daily for up to a week after surgery. The trial's own published result was a negative one: no statistically significant advantage over placebo on its primary efficacy measure, time to tolerating a standard solid meal. Adverse events were common in both arms — reported in roughly 88% of the ipamorelin group and 95% of the placebo group — and included hypokalemia, insomnia, hyperglycemia, nausea, vomiting, and abdominal distention. Two deaths occurred among the surgical patients who had received ipamorelin; FDA's later review of the trial said it remained unclear whether either death was related to the drug.

No controlled human trial of ipamorelin for any purpose beyond these two — the healthy-volunteer pharmacology study and the postoperative-ileus trial — turned up in the published literature FDA reviewed, or in ours.

Why development stopped

Ipamorelin's license moved from Novo Nordisk to Helsinn Therapeutics, which ran the postoperative-ileus trial described above. When that trial missed its efficacy endpoint, clinical development for the indication ended, and no company has since taken ipamorelin through a registrational trial program for any use. FDA's 2024 review also pointed to a practical reason nobody has tried since: an FDA-approved drug, alvimopan, already exists for managing postoperative ileus, narrowing the case for developing a second, unproven option for the same problem.

Where it stands with regulators today

Ipamorelin is not an approved drug anywhere, and no regulator treats its sale as a research chemical as evidence of safety or effectiveness.

In the United States, pharmacies can legally compound certain unapproved substances under Section 503A once FDA adds them to its "bulks list." Ipamorelin, in both its free-base and acetate forms, was nominated for that list, and FDA brought the nominations to its Pharmacy Compounding Advisory Committee on October 29, 2024. The agency's own briefing document for that meeting concluded that the evidence "weighs against" adding either form: the material isn't well characterized from a chemistry standpoint, the only disease trial available showed no benefit, and FDA flagged specific safety signals, including the adverse events from the 2014 surgical trial and a theoretical concern — rooted in ipamorelin's mechanism as a ghrelin-receptor agonist — about "behavioral reinforcing properties" and effects on reproductive health. The committee's advice is non-binding, but as of this writing ipamorelin has not been added to the 503A bulks list. The same FDA document noted that, despite the lack of approval or bulks-list status, outsourcing-facility reporting data showed compounded ipamorelin products reaching patients as early as 2017, and that medical spas and wellness clinics have marketed injectable, nasal, and oral versions for uses the agency's review found no supporting clinical evidence for.

Ipamorelin also sits on the World Anti-Doping Agency's Prohibited List under category S2, covering peptide hormones, growth factors and related substances, banned at all times for athletes in and out of competition. That status isn't theoretical: in August 2026, the International Testing Agency announced a mandatory provisional suspension for South African cyclist S'annara Grove after an out-of-competition sample, collected July 28, 2026, during the Commonwealth Games in Glasgow, returned an adverse finding for ipamorelin.

What's known versus what isn't

What's established: ipamorelin's structure, its receptor target, its selectivity over ACTH and cortisol in animal models, its pharmacokinetics in a small group of healthy men, and the outcome of the one controlled trial run in a surgical-patient population. Those facts come from peer-reviewed publications and FDA's own 2024 administrative record, not from marketing material.

What isn't established is almost everything relevant to the purposes the compound is commonly marketed for. There is no controlled trial of ipamorelin in people with growth-hormone deficiency, in healthy adults, or in any population studied for longer than the week-long surgical trial. FDA's review found no data addressing long-term safety, no human safety data at all for the subcutaneous route most commonly used outside clinical trials (the published human studies used intravenous dosing only), and no independent replication of Raun's original 1998 selectivity findings. The two deaths reported in the surgical trial remain unexplained in the published record — "unclear whether related" is a different finding than "ruled out."

What this means for researchers

Ipamorelin is a genuinely well-characterized molecule at the level of basic pharmacology: its receptor, its selectivity profile, and its pharmacokinetics are documented in peer-reviewed papers going back nearly three decades. What's missing is everything downstream of that — no approved indication, one disease trial that failed to beat placebo, and a 2024 FDA administrative record that reads as a catalog of open safety questions rather than a closed case.

That gap between "well-described molecule" and "studied use" is common among research peptides, and it is worth keeping the two separate. A citation establishing a receptor and a selectivity profile is not evidence that any other use of the compound is safe or effective; those are different questions, and for ipamorelin they mostly haven't been asked in a controlled trial yet. A published lab report can establish what is actually in a given vial, which is a narrower and more answerable question than what the molecule might do. For a related story on a different growth-hormone peptide with its own, separate regulatory path, see Torrey Labs' explainer on tesamorelin.